comparemela.com

Page 4 - Abionyx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company s Share Capital

Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:

Arthur rouillNicolas fossiezLouis victor delouvrierFrench financial markets authorityFrench commercial codeGeneral regulationsEuronext parisVictor delouvrier

ABIONYX Pharma: Annual Results 2021

Cash position of €7.9 million as of December 31, 2021 Positive clinical results throughout the year Strategic partnership with IRIS Pharma to accelerate development in ophthalmology Regulatory

United statesFrance generalIris pharmaArthur rouillValutazioni biologichee farmacologicheLouis victor delouvrierPharma holdingBiologics fareva groupDrug administrationTherapeutics groupUniversity of bariAcute kidney injuryValutazioni biologicheClinical resultsFareva groupDrug designation

ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Rapid reversal of cytokine storm in septic patients Enhanced resolution of biomarkers for inflammation including leukocytosis compared to standard of care No treatment-related serious

Loreto gesualdoArthur rouillCyrille tupinLouis victor delouvrierConnie peyrottesUniversity of bari aldo moroAcute kidney injuryBari aldo moroAnnual resultsVictor delouvrier

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company s Share Capital

Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:

Arthur rouillLouis victor delouvrierFrench financial markets authorityFrench commercial codeGeneral regulationsEuronext parisVictor delouvrier

ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease

ODD follows positive results in two compassionate use cases Published data from compassionate use cases demonstrated for the first time that bio-HDL therapy can reduce lipid deposits in the

France generalArthur rouillLouis victor delouvrierEuropean medicines administrationDrug administrationFisheye diseaseInternal medicineAnnual resultsReverse cholesterol transportVictor delouvrier

vimarsana © 2020. All Rights Reserved.